185 related articles for article (PubMed ID: 35008207)
1. Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity.
Yusenko MV; Biyanee A; Frank D; Köhler LHF; Andersson MK; Khandanpour C; Schobert R; Stenman G; Biersack B; Klempnauer KH
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008207
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824.
Yusenko MV; Klempnauer KH
BBA Adv; 2022; 2():100034. PubMed ID: 37082582
[TBL] [Abstract][Full Text] [Related]
4. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
Klempnauer KH
Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
[TBL] [Abstract][Full Text] [Related]
5. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
6. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
7. Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner.
Biyanee A; Yusenko MV; Klempnauer KH
Cells; 2022 Mar; 11(7):. PubMed ID: 35406726
[TBL] [Abstract][Full Text] [Related]
8. C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.
Yusenko MV; Trentmann A; Casolari DA; Abdel Ghani L; Lenz M; Horn M; Dörner W; Klempnauer S; Mootz HD; Arteaga MF; Mikesch JH; D'Andrea RJ; Gonda TJ; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Oncogene; 2021 Jul; 40(29):4746-4758. PubMed ID: 33958723
[TBL] [Abstract][Full Text] [Related]
9. Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBPβ.
Falkenberg KD; Jakobs A; Matern JC; Dörner W; Uttarkar S; Trentmann A; Steinmann S; Coulibaly A; Schomburg C; Mootz HD; Schmidt TJ; Klempnauer KH
Biochim Biophys Acta Mol Cell Res; 2017 Jul; 1864(7):1349-1358. PubMed ID: 28476645
[TBL] [Abstract][Full Text] [Related]
10. Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.
Schmidt TJ; Klempnauer KH
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408476
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
[TBL] [Abstract][Full Text] [Related]
12. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
[TBL] [Abstract][Full Text] [Related]
13. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
15. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.
Waldron T; De Dominici M; Soliera AR; Audia A; Iacobucci I; Lonetti A; Martinelli G; Zhang Y; Martinez R; Hyslop T; Bender TP; Calabretta B
Leukemia; 2012 Apr; 26(4):644-53. PubMed ID: 21960247
[TBL] [Abstract][Full Text] [Related]
16. Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300.
Uttarkar S; Dukare S; Bopp B; Goblirsch M; Jose J; Klempnauer KH
Mol Cancer Ther; 2015 Jun; 14(6):1276-85. PubMed ID: 25740244
[TBL] [Abstract][Full Text] [Related]
17. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Jiang Y; Gao R; Cao C; Forbes L; Li J; Freeberg S; Fredenburg KM; Justice JM; Silver NL; Wu L; Varma S; West R; Licht JD; Zajac-Kaye M; Kentsis A; Kaye FJ
Oral Oncol; 2019 Nov; 98():147-155. PubMed ID: 31606723
[TBL] [Abstract][Full Text] [Related]
18. MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.
Frech M; Teichler S; Feld C; Bouchard C; Berberich H; Sorg K; Mernberger M; Bullinger L; Bauer UM; Neubauer A
Oncotarget; 2018 Apr; 9(32):22423-22435. PubMed ID: 29854289
[TBL] [Abstract][Full Text] [Related]
19. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
Pattabiraman DR; Sun J; Dowhan DH; Ishii S; Gonda TJ
Mol Cancer Res; 2009 Sep; 7(9):1477-86. PubMed ID: 19737967
[TBL] [Abstract][Full Text] [Related]
20. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.
Lidonnici MR; Corradini F; Waldron T; Bender TP; Calabretta B
Blood; 2008 May; 111(9):4771-9. PubMed ID: 18227349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
